The von Hippel-Lindau tumor suppressor regulates programmed cell death 5-mediated degradation of Mdm2

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Loss of the von Hippel-Lindau (VHL) tumor suppressor protein (pVHL) initiates most clear-cell renal cell carcinomas (ccRCC).
• TP53 gene inactivation is rare in ccRCC, suggesting alternative mechanisms for p53 regulation.
• The p53/Mdm2 pathway's role in VHL-deficient cancers requires further elucidation.

Purpose of the Study:

• To investigate the functional consequences of pVHL loss on the p53/Mdm2 pathway using a zebrafish model.
• To identify novel interactions and mechanisms regulating p53 stability in the context of VHL deficiency and hypoxia.
• To explore potential therapeutic strategies targeting Survivin in ccRCC.

Main Methods:

• Utilized a zebrafish model to study pVHL loss and its effects on p53 and Mdm2.
• Investigated the interaction between pVHL and programmed cell death 5 (PDCD5).
• Assessed cell cycle arrest, apoptosis, and Survivin (BIRC5) expression in VHL-deficient cells and human ccRCC cells.

Main Results:

• pVHL loss leads to p53 stabilization, further enhanced by DNA damage, through a novel interaction with PDCD5.
• Hypoxia or pVHL loss causes PDCD5 nuclear relocalization, leading to Mdm2 degradation.
• Despite p53 hyperstabilization, VHL-deficient cells exhibit resistance to DNA damage due to increased Survivin (BIRC5a) expression.
• Knockdown of Survivin restored caspase activity in human ccRCC cells.

Conclusions:

• A novel mechanism for p53 stabilization via PDCD5 in response to hypoxia or pVHL loss is described.
• Increased Survivin expression confers resistance to DNA damage in VHL-deficient ccRCC.
• Targeting Survivin presents a potential therapeutic strategy for ccRCC and other disorders associated with hypoxic stress.